• Search
  • Helpdesk
  • Sales contact
Get your demo
☰

Scientific advice

The importance of ePRO to support NASH/NAFLD unmet clinical research and medical needs

MetabolicScientific advice
NonAlcoholic SteatoHepatitis (NASH), now called Metabolic Dysfunction-Associated SteatoHepatitis (MASH), affects almost 115 million adults globally and is the most severe form of NonAlcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Liver Disease...

The strengths of electronic Clinical Outcome Assessment (eCOA) versus paper solutions

eCOAScientific advice
In contrast to paper solutions, electronic Clinical Outcome Assessment (eCOA) demonstrates strengths such as:AccuracyCompletenessTimingsAttributabilityUser-friendlinessRegulatory compliance Download the "eCOA vs paper"...

The relevance of ePROs in early phase clinical trials

Scientific advice
Early phase clinical research (phase 1 and 2a) focuses on characterizing the behavior of the investigational product in humans, finding...

Why you should implement a BYOD strategy for your eCOA trial

BYODScientific advice
Improve your clinical trial efficiency and offer more choice to patients by implementing a BYOD strategy for your eCOA trial!...

The shift to data collection at home: Strategies to support flexibility, ensure data quality, and preserve data privacy

Scientific advice
The rate at which we now collect data in clinical trials is astonishing. With decentralization of clinical trials, study data...
,

Decentralized Clinical Trials
Essential tips to avoid common pitfalls

Scientific advice
Despite the numerous advantages of Decentralized Clinical Trials, reducing on-site visit means that data endpoints need to be captured via...
Default Image

Press Release // Kayentis appoints Estelle Haenel as medical director

Scientific advice
25-year pharma industry veteran and clinical trials expert will strengthen Kayentis’ eCOA offering to sponsors seeking to use digital patient-facing...

Kayentis welcomes Estelle Haenel, PharmD, PhD, as Medical Director

Scientific advice
Estelle Haenel has joined Kayentis as Medical Director. She will help leverage the company’s growing medical expertise bringing to Kayentis...
Follow us on social media
Subscribe to our newsletter
You may also like

Rare disease clinical research: it is time to tackle what...

Biotech and eCOA vendor: A shared mindset

The client’s voice: why they consistently choose Kayentis

Why you should join Kayentis

Rethinking pediatric clinical trials: guidelines from pediatric experts

Overcoming challenges in long-lasting pediatric clinical trials – Insights from...

About the author
Picture of Marc Chaperon

Marc Chaperon

Estelle brings 20+ years of experience in pre-clinical and clinical research from Top 5 Pharma and Biotech firms. Leading projects across Phases 1 to 4 in diverse therapeutic areas, she offers deep insights into clinical science, operations, and regulatory intricacies. Appointed as Chief Medical Officer at Kayentis in May 2019.

Kayentis Europe
19 bis, chemin du vieux Chêne
38240 Meylan
France
Phone: +33 (0)4 76 00 54 20

Kayentis US
186 South Street
Suite 600
Boston, Massachusetts 02111
USA